Unless you have been living under a rock, you no doubt have noticed that drug price increases have resulted in a wave of public criticism, playing right into the media’s demonization of the pharmaceutical industry, and even becoming an election year issue. The United States is one of the only developed nations that largely does not restrict the drug prices charged to the public or government. This has led some in the industry to be complacent about the public perception of drug price increases.
While pharmaceutical companies should be able to price their products at whatever level they determine is appropriate without government intervention, the industry would benefit by getting ahead of government regulation and public backlash. The old refrain that high drug prices are justified because drug development costs billions, while true, no longer moves the needle in the debate.
Read the full article: How pharma cos can shape the drug-pricing landscape
Publication
EU Member States may allow companies from countries that have not concluded an agreement guaranteeing equal and reciprocal access to public procurement (public procurement agreement) with the EU to participate in public tenders, provided there is no EU act excluding the relevant country.
Publication
On 11 November 2024, the Financial Reporting Council (FRC) published a consultation document setting out proposed changes to the 2020 UK Stewardship Code (Code).
Publication
Since January 1, 2024, federal legislation in Canada requires companies of a certain size that produce, sell, distribute or import goods into Canada to file a report by May 31 each year regarding the risks of forced labour and child labour in their business and supply chains and the efforts taken to reduce those risks.
Subscribe and stay up to date with the latest legal news, information and events . . .
© Norton Rose Fulbright LLP 2023